New nasal treatment for Alzheimer's disease using allopregnanolone
Official title: Novel Intranasal Formulations of Allopregnanolone, a Regenerative Therapeutic for Alzheimer's Disease
Funded at Neutherapeutics, LLC · NIH-10698555 · Data updated 2026-11-12
This study is testing a new way to deliver a medication called allopregnanolone through the nose to help make it easier for older adults with Alzheimer's disease to take their treatment and feel better.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Neutherapeutics, LLC NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project start | July 15, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $505,836 |
| NIH project number | 1R43AG081024-01A1 |
| Project ID | NIH-10698555 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults diagnosed with Alzheimer's disease who may benefit from new treatment options.
✕Less likely to help
Patients with early-stage Alzheimer's or those not diagnosed with Alzheimer's disease may not receive benefit from this research.
What this research studies
This research focuses on developing a new formulation of allopregnanolone, a neurosteroid, to treat Alzheimer's disease (AD) through an intranasal delivery method. The goal is to create a treatment that is easier for patients to use, especially for older adults who may struggle with other forms of medication administration. The study builds on previous safety trials and aims to address challenges related to long-term use and patient compliance. By optimizing the delivery method, the research seeks to enhance the therapeutic effects of allopregnanolone in managing AD symptoms.
Why it matters
Potential benefit: If successful, this research could provide a more effective and user-friendly treatment option for patients with Alzheimer's disease.
How similar studies have gone: While the use of allopregnanolone has shown promise in previous studies, this specific intranasal formulation is a novel approach that has not been extensively tested.
Where this research is happening
-
Neutherapeutics, LLC
Tucson, United States Active
Researchers
- Principal investigator: Rinehart, John — Neutherapeutics, LLC
- Study coordinator: Rinehart, John
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.